We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biotraces in Blood Samples Can Diagnose Early-Stage Brain Tumor

By LabMedica International staff writers
Posted on 20 Jun 2023

Diagnosing early-stage brain tumors is not only challenging, but certain issues can also arise even after symptoms begin to show. More...

Now, a new, noninvasive method for diagnosing gliomas, one of the deadliest brain tumors, has been developed by researchers. The team achieved this by using Raman spectroscopy to identify chemical compounds known as biotraces, secreted by the tumor, in the blood.

Scientists at Tomsk State University (Tomsk, Russia) initially sourced information from specialized literature about the types of biological markers found in glioma tissues. Following this, they conducted an experiment on lab mice, who were administered human glioblastoma cells. After different time periods, their blood serum was evaluated and the mice were subsequently removed from the study. The scientists utilized Raman spectroscopy to detect specific frequencies which enabled them to find glioma traces in biological fluids, thereby segregating the mice into healthy and afflicted groups. The gathered data was compiled into a library which was used to train a neural network, automating the analysis process.

The researchers believe that this novel method could potentially be beneficial for detecting different types of tumors. All malignant growths secrete unique chemical compounds. If the exact biotraces linked to a particular condition are known, they could be identified using Raman spectroscopy and machine learning. Optical analysis methods are gaining traction across numerous fields, specifically for their potential to quickly diagnose diseases. In line with this, the scientists at TSU are employing AI to develop new noninvasive methods for diagnosing viral and bacterial respiratory infections that can cut down the analysis time from several days to mere minutes.

"What makes our approach advantageous is that it enables us to find traces of an early-stage tumor, prior to symptoms manifesting themselves," said Yury Kistenev, head of the TSU Laboratory of Laser Molecular Imaging and Machine Learning. "The thing is, a glioblastoma changes the biochemical composition of blood. It secretes substances and tumor cells that end up in blood, which carries them around the whole body. By analyzing these biotraces we can get data on cancer formation: That information in turn can be used to diagnosing a disease or monitoring the effectiveness of treatment."

Related Links:
Tomsk State University 


New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Clinical Informatics Platform
CLARION™
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.